We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Hep C Meds Patent Row Can't Stay In Minn., Fed. Circ. Says

Law360, New York (January 17, 2018, 4:17 PM EST) -- The Federal Circuit on Wednesday refused to order that a patent lawsuit brought by the University of Minnesota against Gilead Sciences Inc. over hepatitis C medications be allowed to remain in the North Star State, leaving in place a ruling that found that storage lockers leased by Gilead did not create a place of business.

The appeals court denied a petition for a writ of mandamus from the Regents of the University of Minnesota, which argued that the case should stay in Minnesota because Gilead employees...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re: Regents of the Univ. of Minn.


Case Number

18-112

Court

Appellate - Federal Circuit

Nature of Suit

Date Filed

November 27, 2017

Law Firms

Companies

Government Agencies

Patents

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.